undefined
EUTM file information

018501362

TELOMERE THERAPEUTICS


June 24, 2021

Trademark Summary

The trademark TELOMERE THERAPEUTICS was filed by TELOMERE THERAPEUTICS S.L., a corporation established under the laws of the Kingdom of Spain (the "Applicant"). The application was published for oppositions on August 2, 2021, and received one opposition filed on October 4, 2021 by MONTEPELAYO, S.L.U. on (a) Identity of marks and Goods and Services, (b) Likelihood of confusion. the opponent was represented by González-Mogena González, Iñigo A.

The application was filed in English, and English was also language of all opposition proceedings (Spanish was selected as the second language).


Goods And Services

  • The mark was filed in class 5 with following description of goods:
    1. Pharmaceutical products for the diagnosis and treatment of ageing-related diseases
    2. Pharmaceutical products for the diagnosis and treatment of syndromes and diseases associated with telomere shortening
    3. Pharmaceutical products for the diagnosis and treatment of pulmonary fibrosis, kidney fibrosis, aplastic anemia and dyskeratosis congenita
    4. Reagents, biomarkers and compounds for the diagnosis and treatment of ageing-related diseases
    5. Reagents, biomarkers and compounds for the diagnosis and treatment of syndromes and diseases associated with telomere shortening
    6. Reagents, biomarkers and compounds for the diagnosis and treatment of pulmonary fibrosis, kidney fibrosis, aplastic anemia and dyskeratosis congenita.
  • The mark was filed in class 10 with following description of goods:
    1. Medical devices and apparatus for the diagnosis and treatment of ageing-related diseases
    2. Medical devices and apparatus for the diagnosis and treatment of syndromes and diseases associated with telomere shortening
    3. Medical devices and apparatus for the diagnosis and treatment of pulmonary fibrosis, kidney fibrosis, aplastic anemia and dyskeratosis congenita
    4. Tools for medical diagnostics in the field of ageing-related diseases
    5. Medical therapy instruments for use in the field of ageing-related diseases.
  • The mark was filed in class 35 with following description of goods:
    1. Import, export, retailing and wholesaling of pharmaceutical products, reagents, biomarkers, compounds and medical devices for the diagnosis and treatment of ageing-related diseases
    2. Import, export, retailing and wholesaling of pharmaceutical products, reagents, biomarkers, compounds and medical devices for the diagnosis and treatment of syndromes and diseases associated with telomere shortening
    3. Import, export, retailing and wholesaling of pharmaceutical products, reagents, biomarkers, compounds and medical devices for the diagnosis and treatment of pulmonary fibrosis, kidney fibrosis, aplastic anemia and dyskeratosis congenita
    4. Commercial administration of the licensing of pharmaceutical products, reagents, biomarkers, compounds and medical devices for the diagnosis and treatment of ageing-related diseases
    5. Commercial administration of the licensing of pharmaceutical products, reagents, biomarkers, compounds and medical devices for the diagnosis and treatment of syndromes and diseases associated with telomere shortening
    6. Commercial administration of the licensing of pharmaceutical products and medical devices for the diagnosis and treatment of pulmonary fibrosis, kidney fibrosis, aplastic anemia and dyskeratosis congenita.
  • The mark was filed in class 42 with following description of goods:
    1. Research and development in the field of biotechnology
    2. Research in the field of gene therapy
    3. Biotechnological research in the field of gene therapy and ageing-related diseases
    4. Design and development of pharmaceutical products, medical devices, reagents, biomarkers and compounds for the diagnosis and treatment of ageing-related diseases
    5. Design and development of pharmaceutical products, medical devices, reagents, biomarkers and compounds for the diagnosis and treatment of syndromes and diseases associated with telomere shortening
    6. Design and development of pharmaceutical products, medical devices, reagents, biomarkers and compounds for the diagnosis and treatment of pulmonary fibrosis, kidney fibrosis, aplastic anemia and dyskeratosis congenita
    7. Clinical trials of pharmaceutical products, reagents, biomarkers and compounds for the diagnosis and treatment of ageing-related diseases
    8. Clinical trials of pharmaceutical products, reagents, biomarkers and compounds for the diagnosis and treatment of syndromes and diseases associated with telomere shortening
    9. Clinical trials of pharmaceutical products, reagents, biomarkers and compounds for the diagnosis and treatment of pulmonary fibrosis, kidney fibrosis, aplastic anemia and dyskeratoris congenita.